En Es
Categories

Industry News

QIAGEN Enters into Agreement to Acquire STAT-Dx

By Labmedica International staff writers
13 Feb 2018

Image: Qiagen plans to acquire diagnostics developer STAT-Dx for up to $191 million, in a deal designed to facilitate the buyer's planned launch later this year of the QIAstat-Dx platform, based on STAT-Dx’s proprietary DiagCORE technology (Photo courtesy of STAT-Dx).QIAGEN N.V. (The Netherlands) has entered into an agreement to acquire STAT-Dx (Barcelona, Spain), a privately-held company which develops next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven QIAGEN chemistries.

The system, which will be branded as QIAstat-Dx, enables scalable Sample to Insight processing of up to 48 molecular targets simultaneously for diagnosing syndromes, such as serious respiratory or gastrointestinal infections, as well as for use in oncology. With cost-efficient, easy-to-use assays suitable for any clinical sample type, the system can provide qualitative as well as quantitative insights into the precise cause of various syndromes in about one hour.

Based on the proprietary DiagCORE technology, the system received a first CE-IVD marking in January 2018. The system utilizes cost-efficient, single-use cartridges with built-in sample processing and all reagents on board. The cartridges are loaded with QIAGEN sample and assay technologies and a lab technician only needs to load a clinical sample into a cartridge and place it in the analyzer, requiring less than one minute of hands-on time.

The flexible modular system, which has bi-directional LIS (laboratory information system) interface capabilities, is designed to operate in a range of near-patient clinical settings, eliminating the delay of sending samples to a centralized laboratory. The cartridges are processed in a scalable, proprietary and fully integrated platform, which can be configured from one to eight modules, independently running cartridges with predefined assay protocols and managed via a touchscreen that offers simple step-by-step directions.

QIAstat-Dx is planned to be further developed with the aim of becoming the first analyzer that combines capabilities to run the highest multiplexing molecular diagnostic assays with the ability to quantitate and also process immunoassays. The first two tests, which are extensive respiratory and gastrointestinal (GI) panels, are to be launched in Europe in the second half of 2018, in the US in 2019 following regulatory clearance, and in other markets worldwide. Additional tests are under development for infectious diseases, immune response monitoring, oncology and companion diagnostics.

“QIAstat-Dx represents the next generation of innovation for multiplex syndromic testing, using powerful QIAGEN technologies and a real-time PCR technology that will allow for a much broader range of applications and drive the dissemination of molecular testing. The system is designed for significantly more cost-efficient test processing as required by the current reimbursement environment. Additional application areas for this system include companion diagnostics, quantitative analysis and immunoassay tests, offering customers a new level of flexibility and accurate diagnosis designed to support better outcomes for patients and healthcare systems,” said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. “We look forward to adding QIAstat-Dx to our portfolio of Sample to Insight solutions. This is further confirmation as to how we are leveraging our advantages in sample and assay technologies, our leadership in providing solutions for infectious disease testing and the global reach of our commercial teams.”

“We are excited about accelerating the commercialization of our technology to bring fast, cost-effective syndromic testing closer to care for patients and healthcare providers. At the closing of the transaction, we will build on the achievements of our fantastic team in developing a best-in-class system and leverage QIAGEN’s resources with extensive R&D and commercial reach around the world,” said Jordi Carrera, co-founder and Chief Executive Officer of STAT-Dx.



E-mail Print
FaceBook Twitter Google+ Linked in

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including complete kits for pre-defined applications in sample preparation and analysis, and individual enzymes and reagents. It also offers instruments for automating the full range of laboratory procedures, from the initial sample preparation to the final test result.
More info

More articles about QIAGEN

12 Jan 2017
Qiagen Acquires Bioinformatics Firm OmicSoft
QIAGEN N.V., a provider of sample and assay technologies, has acquired OmicSoft Corporation, which focuses on biomarker data management, visualization, and analysis.
Read More

Additional news

09 May 2018
Health Summit to Play Greater Role in Chinese Health Industry
The Health Industry Summit (tHIS) 2018 held at the National Exhibition and Convention Center in Shanghai on April 11, 2018, was the largest gathering of healthcare industry professionals in the world with well over 200,000 attendees from more than 150 countries and regions and over 7,000 exhibitors. The fourth edition of tHIS covered an exhibition space of over 350,000 square meters with 160 individual events and conferences being held alongside the main expo.
Read More
08 May 2018
Health Summit to Play Greater Role in Chinese Health Industry
The Health Industry Summit (tHIS) 2018 held at the National Exhibition and Convention Center in Shanghai on April 11, 2018, was the largest gathering of healthcare industry professionals in the world with well over 200,000 attendees from more than 150 countries and regions and over 7,000 exhibitors. The fourth edition of tHIS covered an exhibition space of over 350,000 square meters with 160 individual events and conferences being held alongside the main expo.
Read More
07 May 2018
Health Summit to Play Greater Role in Chinese Health Industry
The Health Industry Summit (tHIS) 2018 held at the National Exhibition and Convention Center in Shanghai on April 11, 2018, was the largest gathering of healthcare industry professionals in the world with well over 200,000 attendees from more than 150 countries and regions and over 7,000 exhibitors. The fourth edition of tHIS covered an exhibition space of over 350,000 square meters with 160 individual events and conferences being held alongside the main expo.
Read More
03 May 2018
Global POC Coag Test Market Driven by Increasing Geriatrics
The global point-of-care (POC) coagulation testing market is projected to grow at a CAGR of over 6% during the period 2018-2022, driven by the growing geriatric population, worldwide, and increasing focus on personalized medicine. These are the latest findings of Technavio Research, a global technology research and advisory company.
Read More
03 May 2018
Global PCR Market to Surpass USD 7 Billion by 2025
The global polymerase chain reaction market (PCR) was valued at USD 3.7 billion in 2017 and is projected to grow at a CAGR of 8.8% over the forecast period (2017 – 2025) to surpass USD 7.4 billion by 2025. The extensive applications of the PCR laboratory technique in various fields, rising prevalence and incidence of infectious and chronic diseases, and growing need to develop advanced PCR systems for the rapid and inexpensive quantitative detection of target samples are expected to be the key growth drivers of the PCR market during the forecast period.
Read More
30 Apr 2018
AI-Powered Technology Identifies Abnormalities in CT Scans
A new artificial intelligence (AI)-powered technology can accurately identify bleeds, fractures and other critical abnormalities in head CT scans, and can automatically generate abnormality reports. These automated reports are a first-to-market capability in the AI and radiology category, helping radiologists and hospitals prioritize care, make smarter and faster diagnoses and reduce costs.
Read More
30 Apr 2018
Medical Device Connectivity Market Worth USD 2.7 Billion by 2023
The medical device connectivity market is expected to grow at a CAGR of 23.2% from USD 0.93 billion in 2018 to USD 2.67 billion by 2023. The market growth is likely to be driven by the rising penetration of EHRs & health information exchange systems in healthcare organizations, increasing focus on care quality and patient safety, healthcare IT initiatives boosting the integration of medical devices with hospital information systems, and growing need to control healthcare costs through a connected healthcare environment.
Read More
26 Apr 2018
uAI Platform Brings Future of Intelligent Medicine Closer
United Imaging Healthcare (UIH) has unveiled its new uAI platform, besides introducing three intelligent advanced medical equipment and 10 intelligent diagnostic applications.
Read More
26 Apr 2018
Siemens Healthineers Launches Thermocycler with AI-Powered Software
Siemens Healthineers launched a new molecular thermocycler, the Fast Track cycler (FTC), and the complementary new FastFinder software at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018). The compact FTC allows laboratories of all sizes to implement molecular testing with simplicity and speed, while the FastFinder software improves workflow using Artificial Intelligence (AI)-powered automation.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions